Last $0.0015 USD
Change Today -0.0005 / -25.00%
Volume 61.3K
ABPI On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

accentia biopharmaceuticals (ABPI) Snapshot

Open
$0.0015
Previous Close
$0.0020
Day High
$0.0015
Day Low
$0.0015
52 Week High
10/11/13 - $0.01
52 Week Low
08/11/14 - $0.0011
Market Cap
134.6K
Average Volume 10 Days
53.0K
EPS TTM
$-0.25
Shares Outstanding
89.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCENTIA BIOPHARMACEUTICALS (ABPI)

Related News

No related news articles were found.

accentia biopharmaceuticals (ABPI) Related Businessweek News

No Related Businessweek News Found

accentia biopharmaceuticals (ABPI) Details

Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.

51 Employees
Last Reported Date: 12/26/12
Founded in 2002

accentia biopharmaceuticals (ABPI) Top Compensated Officers

Acting Chief Executive Officer, Acting Chief ...
Total Annual Compensation: $177.3K
Chief Scientific Officer
Total Annual Compensation: $185.0K
Compensation as of Fiscal Year 2012.

accentia biopharmaceuticals (ABPI) Key Developments

Accentia Biopharmaceuticals, Inc. announced delayed 10-Q filing

On 08/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Shapiro Haber & Urmy LLP and Liggio Benrubi PA Files Class Action Lawsuit Against Accentia Biopharmaceuticals, Inc. and Officers and Directors of Accentia and Biovest International, Inc

Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (ABPI) and certain officers and directors of Accentia and Biovest International, Inc., a majority-owned subsidiary of Accentia, for violations of federal securities laws. The case has been filed in the United States District Court for the Middle District of Florida and is entitled Hill v. Accentia Biopharmaceuticals, et al., C.A. No. 13-cv-01945. The Complaint alleges that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Despite this information, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that the trial results were statistically significant and that Biovest was on track to obtain FDA approval. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act. The class action is brought on behalf of all persons and entities who purchased common stock of either Accentia or Biovest from July 26, 2008 through August 14, 2012.

Accentia Biopharmaceuticals, Inc. announced delayed 10-Q filing

On 05/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABPI:US $0.00 USD -0.0005

ABPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABPI.
View Industry Companies
 

Industry Analysis

ABPI

Industry Average

Valuation ABPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCENTIA BIOPHARMACEUTICALS, please visit www.accentia.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.